New Report Highlights UAE's Leadership And Collaborative Roadmap For Transforming Alzheimer's Disease Care
(MENAFN- Mid-East Info)
Globally, more than 55 million people live with dementia[1], with Alzheimer's Disease being the most common form[2]. The report outlines proactive and progressive measures taken by the UAE to address the growing burden of Alzheimer's Disease amid increasing lifespans and an aging population. These include awareness efforts by the UAE's Ministry of Health and Prevention (MoHAP) and charitable organizations like 4-get-me-not, as well as Sharjah's recognition by WHO as the first Arab Age Friendly City in the Middle East in 2015, serving as a model for other cities on best practices in healthy aging. To further reinforce the UAE's position as a leader in healthcare infrastructure and policy, and enhance health outcomes for people with Alzheimer's Disease, the report calls for investment in three focus areas. First, a dedicated policy or national plan for Alzheimer's Disease, with the involvement of multidisciplinary stakeholders across government, industry and academia, as well as patients and caregivers, will help guide a coordinated and evidence-based response. Furthermore, training and upskilling healthcare professionals, particularly primary care providers who are often the first point of contact for people with Alzheimer's Disease, will help create a clearer pathway for patients enabling earlier diagnosis and interventions. Finally, further investment in public education can address stigma and misconceptions and ensure that people are aware of the early signs, and know where and how they can seek support. “Breakthroughs in science are transforming how we detect and treat Alzheimer's Disease, enabling more efficient care. However, realizing the full impact of these advancements depends on strategic collaboration to ensure they reach patients effectively,” said Roberta Marinelli, Eli Lilly President and General Manager for Middle East and Turkiye . “Lilly's 35 years of pioneering research in Alzheimer's Disease has taught us one lesson: progress happens faster when we act together. By partnering with the UAE's healthcare community, we are determined to set benchmarks that not only transform care locally but also shape global practice.” The report titled 'Changing the Narrative: Alzheimer's Disease in the UAE' was launched at the 5th Abu Dhabi Brain Conference, where international leaders in neuroscience gathered to drive innovation in brain health. The focus on Alzheimer's Disease reflects a strategic push for policy change, innovation, and integrated care models, with the report serving as a platform to advance this dialogue. The report provides a clear, evidence-based roadmap for the UAE to strengthen its leadership in healthcare and redefine how nations respond to Alzheimer's Disease. About Lilly:
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
-
A recent UAE report highlights the country's proactive efforts to tackle the rising challenges of Alzheimer's Disease and sets out an actionable roadmap to reinforce the country's leadership in global healthcare.
The report was drafted by The Economist Impact and Commissioned by Eli Lilly, the global leader in Alzheimer's research and innovation.
Globally, more than 55 million people live with dementia[1], with Alzheimer's Disease being the most common form[2]. The report outlines proactive and progressive measures taken by the UAE to address the growing burden of Alzheimer's Disease amid increasing lifespans and an aging population. These include awareness efforts by the UAE's Ministry of Health and Prevention (MoHAP) and charitable organizations like 4-get-me-not, as well as Sharjah's recognition by WHO as the first Arab Age Friendly City in the Middle East in 2015, serving as a model for other cities on best practices in healthy aging. To further reinforce the UAE's position as a leader in healthcare infrastructure and policy, and enhance health outcomes for people with Alzheimer's Disease, the report calls for investment in three focus areas. First, a dedicated policy or national plan for Alzheimer's Disease, with the involvement of multidisciplinary stakeholders across government, industry and academia, as well as patients and caregivers, will help guide a coordinated and evidence-based response. Furthermore, training and upskilling healthcare professionals, particularly primary care providers who are often the first point of contact for people with Alzheimer's Disease, will help create a clearer pathway for patients enabling earlier diagnosis and interventions. Finally, further investment in public education can address stigma and misconceptions and ensure that people are aware of the early signs, and know where and how they can seek support. “Breakthroughs in science are transforming how we detect and treat Alzheimer's Disease, enabling more efficient care. However, realizing the full impact of these advancements depends on strategic collaboration to ensure they reach patients effectively,” said Roberta Marinelli, Eli Lilly President and General Manager for Middle East and Turkiye . “Lilly's 35 years of pioneering research in Alzheimer's Disease has taught us one lesson: progress happens faster when we act together. By partnering with the UAE's healthcare community, we are determined to set benchmarks that not only transform care locally but also shape global practice.” The report titled 'Changing the Narrative: Alzheimer's Disease in the UAE' was launched at the 5th Abu Dhabi Brain Conference, where international leaders in neuroscience gathered to drive innovation in brain health. The focus on Alzheimer's Disease reflects a strategic push for policy change, innovation, and integrated care models, with the report serving as a platform to advance this dialogue. The report provides a clear, evidence-based roadmap for the UAE to strengthen its leadership in healthcare and redefine how nations respond to Alzheimer's Disease. About Lilly:
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- New Cryptocurrency Mutuum Finance (MUTM) Raises $15.8M As Phase 6 Reaches 40%
- Bydfi Joins Korea Blockchain Week 2025 (KBW2025): Deepening Web3 Engagement
- Yield Basis Nears Mainnet Launch As Curve DAO Votes On Crvusd Proposal
- 0G Labs Launches Aristotle Mainnet With Largest Day-One Ecosystem For Decentralized AI
- Ethereum-Based Defi Crypto Mutuum Finance (MUTM) Raises Over $16 Million With More Than 720M Tokens Sold
- Fintech's Gender Gap In Focus: Drofa Comms' Women Leading The Way Joins Evolvh3r's She Connects At TOKEN2049
More Story
Comments
No comment